Research Studies
Back to Results
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Details
Age
Adult
Type of Study
Treatment
Location
University of Colorado Hospital
Principal Investigator
Thomas Flaig, MD
Study ID
Protocol Number: 20-0035
More information available at ClinicalTrials.gov: NCT04223856
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers